1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties

Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents

(2021) Angela Fan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

(2020) Justin T. Ernst et al.   JOURNAL OF MEDICINAL CHEMISTRY

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

(2020) David E. Gordon et al.   NATURE

Strategic Diastereoselective C1 Functionalization in the Aza-Rocaglamide Scaffold toward Natural Product-Inspired eIF4A Inhibitors

(2020) Christian Nilewski et al.   ORGANIC LETTERS

Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses

(2020) Canan G. Nebigil et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Targeting oncogene mRNA translation in B cell malignancies with eFT226, a potent and selective inhibitor of eIF4A1

(2020) Peggy A Thompson et al.   MOLECULAR CANCER THERAPEUTICS

Intercepted Retro-Nazarov Reaction: Syntheses of Amidino-Rocaglate Derivatives and Their Biological Evaluation as eIF4A Inhibitors

(2019) Wenhan Zhang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA

(2018) Shintaro Iwasaki et al.   MOLECULAR CELL

Development of Safe Drugs: The hERG Challenge

(2017) Subha Kalyaanamoorthy et al.   MEDICINAL RESEARCH REVIEWS

Recent Advances in the Synthesis of Flavaglines, a Family of Potent Bioactive Natural Compounds Originating from Traditional Chinese Medicine

(2016) Qian Zhao et al.   EUROPEAN JOURNAL OF ORGANIC CHEMISTRY

Targeting the translation machinery in cancer

(2015) Mamatha Bhat et al.   NATURE REVIEWS DRUG DISCOVERY

The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape

(2015) A Modelska et al.   Cell Death & Disease

Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase

(2014) J. J. Steinhardt et al.   BLOOD

Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines)

(2014) Min Li-Weber   INTERNATIONAL JOURNAL OF CANCER

Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species

(2014) Li Pan et al.   NATURAL PRODUCT REPORTS

Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex

(2013) Heather Sadlish et al.   ACS Chemical Biology

A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma

(2013) E Horvilleur et al.   LEUKEMIA

Flavaglines as Potent Anticancer and Cytoprotective Agents

(2012) Nigel Ribeiro et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors

(2012) Tao Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mitigating Heterocycle Metabolism in Drug Discovery

(2012) David J. St. Jean et al.   JOURNAL OF MEDICINAL CHEMISTRY

The DEAD-box helicase eIF4A

(2012) Alexandra Z. Andreou et al.   RNA Biology

Recent advances in the biology and chemistry of the flavaglines

(2011) Nigel Ribeiro et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Synthesis of Rocaglamide Hydroxamates and Related Compounds as Eukaryotic Translation Inhibitors: Synthetic and Biological Studies

(2011) Christina M. Rodrigo et al.   JOURNAL OF MEDICINAL CHEMISTRY

mRNA helicases: the tacticians of translational control

(2011) Armen Parsyan et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Oxetanes in Drug Discovery: Structural and Synthetic Insights

(2010) Georg Wuitschik et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel Flavaglines Displaying Improved Cytotoxicity

(2010) Frédéric Thuaud et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One